Mental Health

Autism spectrum disorder

Autism is a lifelong neurodevelopmental difference involving persistent social-communication and interaction differences together with restricted, repetitive patterns of behaviour, interests or activities, present from the early developmental period and associated with support needs or functional impact.

In a nutshell

Autism is a lifelong neurodevelopmental difference involving both social-communication and interaction differences and restricted, repetitive patterns of behaviour, interests or activities, present from the early developmental period. Diagnosis is specialist and clinical; tools support referral or complex assessment but do not diagnose alone. Management is person-centred and focuses on communication, environmental adjustments, life skills, comorbidity, sleep, nutrition, safeguarding and behaviour that challenges. No medication treats the core features; antipsychotics and melatonin have narrow specialist indications and require measurable goals and review.

Classic presentation

A child or adult has a lifelong pattern of social-communication difference and restricted or repetitive behaviour or interests, with sensory or routine-related needs and functional impact. Assessment integrates developmental history, collateral information, direct observation and coexisting physical and mental health; a fluent or apparently coping adult is not excluded.

Key points

  • Both core domains are required: social communication and interaction differences plus restricted, repetitive behaviours, interests or activities.
  • Features arise in the early developmental period but may be recognised only when social or occupational demands increase; masking does not exclude autism.
  • Diagnosis is clinical and multidisciplinary; screening tools, AQ-10, ADOS or ADI-R support assessment but do not diagnose or rule out autism alone.
  • Regression, seizures, acute behaviour change, severe self-injury, safeguarding risk, restricted diet or unexplained pain require targeted medical or safety assessment.
  • There is no drug treatment for core autistic features. Treat coexisting conditions and use functional, psychosocial and environmental approaches for behaviour that challenges.
  • Specialist antipsychotic treatment is a time-limited, measurable trial only after psychosocial approaches are insufficient or impossible because behaviour is severe; review at 3 to 4 weeks and stop at 6 weeks without clinically important response.
  • For children, use a sleep plan before specialist melatonin; assess feeding, growth, hydration and nutritional deficiency, and plan transition and reasonable adjustments around the person's needs.

First-line investigation

Specialist developmental and multidisciplinary autism assessment with collateral history, direct observation and assessment of support needs, coexisting conditions, sensory needs and function; use targeted hearing, vision, EEG or genetic assessment only when clinically indicated.

Management

Assess, explain and adapt care

  • Use a specialist developmental and multidisciplinary assessment with collateral history and direct observation; provide an accessible explanation, health passport or crisis plan where useful, and coordinate education, health, mental-health and social-care support.1,2,7
  • Make communication and environmental adjustments explicit: predictable structure, visual or written information, sensory adaptations, reasonable adjustments and person-preferred involvement of family or carers.5,2,9

Treat needs and behaviour by function

  • Investigate pain, constipation, sleep, seizures, mental disorder, communication difficulty, sensory overload, routine change and safeguarding concerns before attributing distress or behaviour that challenges to autism.5,2
  • Use an individualised psychosocial intervention based on functional analysis, defined target behaviours, quality-of-life outcomes, environmental modification and systematic review.5,2,8

Reserve medication for narrow indications

  • Do not use medicines for core autistic features. Consider a specialist antipsychotic for severe behaviour that challenges only after psychosocial or other interventions have been insufficient or could not be delivered; use measurable goals and the lowest effective exposure.5,2,6,10
  • Review at 3 to 4 weeks and discontinue at 6 weeks if there is no clinically important response; monitor physical health, adverse effects, quality of life, target behaviours and the stopping plan.5,2,8

Protect sleep, nutrition and mental health

  • Use a behavioural sleep plan first in children; specialist melatonin is considered only when sleep remains harmful despite the plan, alongside non-pharmacological measures and regular review. Assess restrictive diet, growth, hydration and nutritional deficiency.5,10
  • Treat ADHD, anxiety, depression, eating disorder, epilepsy and physical illness using adapted NICE pathways; use urgent mental-health and safeguarding escalation for suicidality, psychosis, severe self-injury, exploitation or loss of safety.5,2,11

Plan transition and review support needs

  • Reassess support around adolescence and adult transition, covering education, employment, housing, daily living, driving, relationships, carers, crisis planning and continuity between services.5,2,4

Exam traps

  • Both diagnostic domains are required; isolated language delay, ADHD or social anxiety does not establish autism, although these conditions can coexist.
  • A screening score, ADOS, ADI-R or a negative childhood history alone does not make or exclude the diagnosis; interpret developmental and cross-context evidence clinically.
  • Do not attribute regression, seizures, pain, constipation, sleep apnoea, restricted diet or sudden behaviour change to autism without targeted medical assessment.
  • Antipsychotics do not treat core autistic features; for behaviour that challenges, identify physical, mental-health, communication and environmental triggers first.
  • If an antipsychotic is used, define target behaviour and quality-of-life outcomes, review at 3 to 4 weeks and stop at 6 weeks if no clinically important response.
  • Melatonin in autistic children is specialist advice after a sleep plan has failed and should be combined with non-pharmacological measures and regularly reviewed.
  • Respect preferred language, communication needs and autonomy; a person who masks or appears socially fluent may still need substantial support.

Key sources

  1. NICE CG128, Autism spectrum disorder in under 19s: recognition, referral and diagnosis (NICE clinical guideline published 28 September 2011, last updated 20 December 2017; minor updates in 2022 and April 2025, including current ICD-11, psychologist wording and MHRA valproate/topiramate notes)
  2. NICE CG142, Autism spectrum disorder in adults: diagnosis and management (NICE clinical guideline published 27 June 2012, last updated 14 June 2021; September 2025 exceptional surveillance reviewed coexisting mental-health recommendations and decided not to update them)Updated 5 Sept 2025
  3. NHS, What is autism? (Current NHS overview reviewed 6 May 2026 covering autism as a developmental difference, variable communication and sensory features, coexisting conditions and vaccine safety)Updated 6 May 2026
  4. NHS England, Autism (Current NHS England commitments on diagnostic pathways, reasonable adjustments, autistic mental-health care, keyworkers and STOMP/STAMP)
  5. NICE CG170, Autism spectrum disorder in under 19s: support and management (NICE clinical guideline published 28 August 2013, last updated 14 June 2021; current recommendations on social communication, behaviour that challenges, sleep, melatonin, feeding/nutrition, mental health and transition)Updated 14 Jun 2021
  6. NHS England, STOMP and STAMP (Current NHS England medication-safety programme describing specialist initiation, defined target behaviours, monitoring, review and reduction of inappropriate psychotropic medication in learning disability and autism)
  7. NHS, Autism assessments (Current NHS information reviewed 6 May 2026 covering referral, specialist assessment, history, physical examination and support while waiting)Updated 6 May 2026
  8. NICE NG11, Challenging behaviour and learning disabilities (NICE principles for functional assessment, psychosocial interventions, specialist antipsychotic prescribing and review when behaviour that challenges occurs with learning disability)
  9. NHS, Help and support for autistic people and their families (Current NHS support information reviewed 6 May 2026 covering local autism teams, council, education, work, social and national support)Updated 6 May 2026
  10. BNF and BNF for Children, autism-related prescribing (Current UK prescribing source for specialist review of antipsychotics, melatonin and coexisting-condition medicines; detailed dose claims are intentionally omitted because BNF access was restricted in this environment)
  11. NHS, Autism and adult life (Current NHS information reviewed 6 May 2026 covering variable support needs, physical and mental health, fatigue, daily living, transition and carers)Updated 6 May 2026

This page is exam revision material, not medical advice, and must not be used for patient care. Always check drug doses against the BNF and current guidance. Full disclaimer.